Search clinical trials for: Phentolamine mesylate

Total 1680 results

Ocuphire Pharma, Inc.

Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Night Vision Complaints | Decrease in Night Vision | Disturbance; Vision, Loss

United States
Ocuphire Pharma, Inc.
Ophthalmic Consultants of Long Island

Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances (SNV)

Decrease in Night Vision | Disturbance; Vision, Loss

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Ocular Hypertension | Open Angle Glaucoma

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Mydriasis | Dilation

United States
Novalar Pharmaceuticals, Inc.

Completed

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures

Anesthesia, Dental

United States
Novalar Pharmaceuticals, Inc.

Completed

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

Anesthesia, Dental

United States
Novalar Pharmaceuticals, Inc.

Completed

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures

Anesthesia, Dental

United States
Novalar Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NV-101 in Dental Patients

Soft Tissue Anesthesia (Numbness)

United States
Dalhousie University

Completed

Reversing the Effects of 0.5% Bupivacaine

Anesthesia, Local

Canada
Cairo University

Not yet recruiting

Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children

Soft Tissue Injuries
Dalhousie University

Completed

Reversing the Effects of 2% Lidocaine

Soft Tissue Anaesthesia

Canada
León Formación

Completed

Phentolamine Mesylate as a Reversal of Local Anesthesics

Anesthesia, Local
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Mydriasis | Dilation

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Dim Light Vision Disturbances

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) (MIRA-3)

Mydriasis | Dilation

United States
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Unknown

The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

Heart Failure, Congestive

Netherlands
University of Bologna

Completed

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

Italy
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Ocuphire Pharma, Inc.

Completed

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects (MIRA-4)

Mydriasis | Dilation

United States
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Refractory Desmoplastic Small Round Cell Tumors

Italy
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Presbyopia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Prostate Cancer

United States
Helwan University
University of Nebraska

Completed

The Use of Disinfectants Among Women in Egypt and the Toxicity by Bleach During the Coronavirus Lock-down.

Toxicity by Bleach

Egypt
University of Missouri-Columbia

Recruiting

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Healthy | Obesity | Vasodilation

United States
Ocuphire Pharma, Inc.
Viatris Inc.

Recruiting

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2)

Mesopic Vision | Night Vision Loss

United States
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Xuanwu Hospital, Beijing

Completed

Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease

Parkinson's Disease

China
Xu J

Recruiting

New Perspective on Exploring the Post-apneic BP Surge in Patients With OSA

Obstructive Sleep Apnea

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Eisai Inc.

Completed

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer

Netherlands
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (EMBRAVE-001)

Triple Negative Breast Cancer

China
National Cancer Institute (NCI)

Completed

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States

3

Subscribe